Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 1

Status

Completed 6Terminated 2Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Myeloid 6

Conditions

Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Glioblastoma 7Polycythemia Vera 6Gliosarcoma 6Leukemia 5Head and Neck Neoplasms 5Meningioma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Neoplasms 3Myelodysplastic Syndromes 3Laryngeal Neoplasms 3Central Nervous System Neoplasms 3Thrombocythemia, Essential 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Pharyngeal Neoplasms 2Paranasal Sinus Neoplasms 2Oropharyngeal Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Hypopharyngeal Neoplasms 2Glioma 2Congenital Abnormalities 2Carcinoma, Squamous Cell 2Astrocytoma 2

Interventions

fludarabine phosphate 20Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 17Busulfan 16ruxolitinib 14Tacrolimus 12Whole-Body Irradiation 9Mycophenolic Acid 9Methotrexate 8Antilymphocyte Serum 8Cyclosporine 7peginterferon alfa-2a 6Hydroxyurea 6Filgrastim 6Etoposide 6Aspirin 6fludarabine 5Prednisone 5Melphalan 5Imatinib Mesylate 5Cytarabine 5Decitabine 4pomalidomide 3givinostat hydrochloride 3givinostat 3Topotecan 3Thiotepa 3Radiotherapy 3Lenalidomide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Polycythemia Vera × Hydroxyurea × Clear all
NCT01387763 2022-04-27

DALIAH

Odense University Hospital

Phase 3 Completed
202 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00928707 2019-10-31

PV

Italfarmaco

Phase 2 Completed
45 enrolled 10 charts
Myeloid

Polycythemia Vera

NCT01259856 2019-04-30

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 3 Completed
168 enrolled 16 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Incyte Corporation

Phase 3 Completed
222 enrolled 21 charts
Myeloid

Polycythemia Vera

NCT01632904 2017-11-14

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Incyte Corporation

Phase 3 Completed
110 enrolled 11 charts
Myeloid

Polycythemia Vera

NCT01949805 2016-11-28

PROUD-PV

AOP Orphan Pharmaceuticals AG

Phase 3 Completed
257 enrolled
Myeloid

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡